FDA Reverses Course on Gene Therapy for Huntington’s Disease

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

Huntington's disease is an inherited brain disorder that slowly destroys a person's ability to move, think, and control emotions.

FDA reversal opens path.Earlier this year, the FDA publicly rejected UniQure's gene therapy data, blocking progress. Now the agency has cleared the way for accelerated approval, giving patients a treatment option they did not have before.
Accelerated approval possible.UniQure can now apply for accelerated approval in the third quarter, a much faster route than standard approval. This means patients could potentially access the therapy years sooner than originally expected.
Direct brain delivery.The therapy is injected directly into the brain, targeting the root cause of Huntington's at its source. Before this, no approved treatment addressed the underlying genetic damage, only symptoms.
Hope for inherited disease.Huntington's is passed down through families, and until now there were no disease modifying therapies available. This gene therapy offers the first real chance to slow or stop the destruction of nerve cells for thousands of patients.

The U.S. Food and Drug Administration has cleared a path for UniQure to seek accelerated approval of its experimental gene therapy for Huntington’s disease, a stunning reversal from earlier this year when the agency publicly rejected the very same data. The company plans to submit its application in the third quarter, offering new hope to patients with this devastating inherited neurological disorder.

Huntington’s disease gradually destroys nerve cells in the brain, robbing patients of motor control, cognitive function, and emotional stability. UniQure’s therapy, delivered directly into the brain through a hours-long surgical procedure, aims to slow the disease’s progression. In a Phase 1/2 trial, the treatment slowed disease progression by 75 percent when compared to the typical course of the disease using an external database. The company had argued that a sham surgery for a placebo-controlled trial would be unethical, and the FDA now agrees that the existing data can support an accelerated approval.

Under accelerated approval, the therapy could reach patients before a confirmatory study is completed. The FDA and UniQure have agreed to design that follow-up study using the current standard of care as a comparison instead of a sham procedure. The agency stated it “remains committed to working with UniQure to identify a regulatory pathway that serves patients with Huntington’s disease and their families, while upholding the agency’s commitment to gold-standard science.”

A Shift in Regulatory Winds

This decision marks a sharp departure from the stance taken under former FDA Commissioner Marty Makary, who left the agency in May. In February, Makary described the therapy without naming it, telling CNBC the agency had been pressured to approve a treatment that showed “no benefit.” Senior FDA officials at the time insisted that UniQure run a placebo-controlled trial to prove the therapy “actually helps people.” The company’s fortunes, along with those of other rare disease drugmakers, now appear to have shifted following the departure of Makary and other senior leaders.

For patients and families living with Huntington’s disease, the news offers a tangible sense of progress. If approved, UniQure’s gene therapy would become the first treatment to directly target the underlying genetic cause of the disease. The company expects to finalize plans for the confirmatory study before submitting its application, and the FDA has signaled willingness to work collaboratively on the path forward.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.